Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 129 for “"Olaparib"”.

  1. Olaparib και σχετιζόμενοι μοριακοί βιοδείκτες στον καρκίνο του μαστού - Συστηματική Ανασκόπηση

    … και ελπιδοφόρα αποτελέσματα. Ο αναστολέας PARP, Olaparib, εγκρίθηκε πρόσφατα από τον FDA, για τη θεραπεία του καρκίνου των ωοθηκών, του μαστού και του προστάτη υπό συγκεκριμένες προϋποθέσεις με την πιο βασική να είναι η παρουσία γαμετικών μεταλλαγών στα γονίδια BRCA1/2. Στην παρούσα συστηματική …

    athens Repository record for Olaparib και σχετιζόμενοι μοριακοί βιοδείκτες στον καρκίνο του μαστού - Συστηματική Ανασκόπηση (opens in a new tab)

  2. Nanomedicines and Combination Therapy of Doxorubicin and Olaparib for Treatment of Ovarian Cancer

    … studies of DOX together with the PARP inhibitor, olaparib (OLP, Lynparza ® ) were conducted in 2D monolayers and 3D MCTS. In these studies, the effectiveness of the DOX:OLP combination therapy in monolayers and MCTS was found to be ratio dependent such that equimolar ratios resulted in an additive …

    toronto-retro Repository record for Nanomedicines and Combination Therapy of Doxorubicin and Olaparib for Treatment of Ovarian Cancer (opens in a new tab)

  3. Comparative Transcriptomic Analysis of Olaparib and Atezolizumab Responses in Triple-Negative Breast Cancer Cell Lines

    … associated with TNBC following treatment with Olaparib (a PARP inhibitor) and Atezolizumab (an anti-PD-L1 antibody), administered individually and in combination, in two TNBC cell lines representing different biological backgrounds: MDA-MB-157 (African American) and MDA-MB-231 (Caucasian), …

    houston Repository record for Comparative Transcriptomic Analysis of Olaparib and Atezolizumab Responses in Triple-Negative Breast Cancer Cell Lines (opens in a new tab) Embargoed until 2028-05-01

  4. Efeito citotóxico do Olaparib em células de câncer colorretal : estudo da influência de defeitos genéticos

    … este motivo, neste trabalho, a citotoxicidade do Olaparib (um inibidor de PARP) foi investigada em um painel de linhagens de câncer colorretal (CRC). Os resultados demonstraram que o Olaparib é uma droga de ação lenta, cuja citotoxicidade pode ser modulada por defeitos genéticos em MLH1 (envolvido …

    brazil-ufrgs Repository record for Efeito citotóxico do Olaparib em células de câncer colorretal : estudo da influência de defeitos genéticos (opens in a new tab)

  5. Vergleich des strahlenverstärkenden Effekts des PARP-Inhibitors Olaparib auf unterschiedliche Strahlenqualitäten an einem Prostatakarzinom-Zellmodell

    … Arbeit ist, die Effektivität des PARP-Inhibitors Olaparib in Kombination mit verschiedenen Strahlenqualitäten (α- und β-Partikelstrahlung, externe Röntgenstrahlung) und oIH + UVA am PC-3-Zellmodell des Prostatakarzinoms mit verschiedenen biologischen Endpunkten zu überprüfen. Material und Methode: …

    qucosa-diss

  6. Combined chemo-radiotherapy utilising Olaparib and Mirin in combination with X-rays and targeted radionuclide therapy

    … research. Mirin, an MRN complex inhibitor, and Olaparib, a PARP-1 inhibitor, are two such compounds that have been predicted to enhance radiotherapy Aims: The aims of the present study were to determine the radiosensitising potential of Mirin and Olaparib in combination with X-ray radiation and …

    strathclyde Repository record for Combined chemo-radiotherapy utilising Olaparib and Mirin in combination with X-rays and targeted radionuclide therapy (opens in a new tab)

  7. PHARMACOLOGICAL INHIBITION OF NUCLEAR FACTOR OF ACTIVATED T-CELLS REDUCES GLIOBLASTOMA VIABILITY AND SYNERGIZES WITH OLAPARIB

    … with poly-ADP-ribose polymerase (PARP) inhibitor olaparib. Specifically, we addressed three key questions: (1) how NFAT inhibition impacts cell viability, apoptosis, and migration in vitro; (2) how NFAT inhibition affects survival and tumor growth in glioblastoma rodent models; and (3) how NFAT …

    jhu Repository record for PHARMACOLOGICAL INHIBITION OF NUCLEAR FACTOR OF ACTIVATED T-CELLS REDUCES GLIOBLASTOMA VIABILITY AND SYNERGIZES WITH OLAPARIB (opens in a new tab)

  8. Targeting PDK and PARP to improve radiation response in preclinical models of non-small cell lung cancer

    … targeting DNA repair with the PARP inhibitor olaparib. The <em>in vitro</em> radiosensitising effect of the PARP inhibitor olaparib and the PDK1 inhibitors BX912 and GSK2334470 was determined using clonogenic survival assays. The combination of PDK1 inhibitors with radiation did not increase …

    oxford Repository record for Targeting PDK and PARP to improve radiation response in preclinical models of non-small cell lung cancer (opens in a new tab)

  9. Collateral Sensitivity Associated with Multidrug-Resistance Protein 5 in Triple-Negative Breast Cancer

    … in breast cancer. In this study, we investigated olaparib accumulation and sensitivity in ABCC5-overexpressing HEK293 (HEK-MRP5) and ABCC5 gene knockout (KO) TNBC cell models. The potential upstream regulators of ABCC5 were also studied in the respective gene KO cell model. Overexpression of ABCC5 …

    auckland-tech Repository record for Collateral Sensitivity Associated with Multidrug-Resistance Protein 5 in Triple-Negative Breast Cancer (opens in a new tab)

  10. 3-in-1 Nanotherapeutic Strategies for Ovarian Cancer

    … mechanisms that prevent effective cytotoxicity. Olaparib and metformin have improved cisplatin sensitivity by targeting these two mechanisms, respectively. Although previous studies have demonstrated that cisplatin combined with either olaparib or metformin have shown stronger efficacy than a …

    ottawa-retro Repository record for 3-in-1 Nanotherapeutic Strategies for Ovarian Cancer (opens in a new tab)

  11. PARylation and Prostate Cancer – Effects of PARP Inhibition on the Androgen Receptor

    … have shown the efficacy of PARP inhibitors like olaparib to kill castration-resistant prostate cancer (CRPC) cells that have DNA repair defects (Langelier, Riccio, and Pascal 7762-7775). Olaparib is approved for the treatment of ovarian and breast cancers harboring BRAC1/2 mutations. However, …

    jhu Repository record for PARylation and Prostate Cancer – Effects of PARP Inhibition on the Androgen Receptor (opens in a new tab)

  12. Exploring novel nanomedicine-based PARP inhibitor delivery systems: in vitro and in vivo studies in healthy mice

    Olaparib is a poly (ADP-ribose) polymerase inhibitor (PARPi) used to treat breast cancer (BRCA)-deficient tumours. It also functions as an effective radiotherapy sensitiser by blocking the PARP-based DNA repair mechanism. However, olaparib has limited bioavailability and suboptimal pharmacokinetic …

    kings Repository record for Exploring novel nanomedicine-based PARP inhibitor delivery systems: in vitro and in vivo studies in healthy mice (opens in a new tab) Download PDF for Exploring novel nanomedicine-based PARP inhibitor delivery systems: in vitro and in vivo studies in healthy mice (opens in a new tab)

  13. Preclinical Models to study the Biology and Therapy of Ovarian Cancer

    … of the high grade serous (HGS) ovarian cancer. Olaparib, a PARP inhibitor affecting DNA damage repair pathway, has been approved in the treatment of germline-<i>BRCA</i>-mutated patients. The combination with cediranib, an angiogenesis inhibitor, has shown promising results, increasing …

    the-open-u Download PDF for Preclinical Models to study the Biology and Therapy of Ovarian Cancer (opens in a new tab)

  14. Identifying and overcoming mechanisms of resistance to Wee1 kinase inhibitor (AZD1775) in high grade serous ovarian cancer

    … Given the increased use of the PARP inhibitor olaparib as a therapy for HGSOC, olaparib resistant clones were also isolated from the same HR-deficient and proficient HGSOC cell lines with the supplementary aim of investigating the effectiveness of AZD1775 therapy in olaparib resistant HGSOC. I …

    edinburgh Repository record for Identifying and overcoming mechanisms of resistance to Wee1 kinase inhibitor (AZD1775) in high grade serous ovarian cancer (opens in a new tab)

  15. ATM-deficient cancer cells and targeted therapies

    … pancreatic cancer cell lines are sensitive to olaparib (a PARP inhibitor) and that ATM-deficient pancreatic cancer cell lines are sensitive to the PARP inhibitor Rucaparib as well as the ATR inhibitor VE-821. Using both lung and colorectal cancer cells, I also show that olaparib induces DNA …

    calgary Repository record for ATM-deficient cancer cells and targeted therapies (opens in a new tab)

  16. Targeting DNA damage and repair mechanism in FLT3-ITD acute myeloid leukemia – a mechanistic and therapeutic study

    … Flt3 ITD/+ Npm1 c/+ mouse leukemic cells, PARPi Olaparib suppressed leukemia growth in vitro. Combination of chemotherapy and Olaparib worked synergistically to eradicate leukemic cells in MOLM-13 murine xenograft model. Biochemically, Olaparib inhibited base excision repair and increased the DSB …

    kings Repository record for Targeting DNA damage and repair mechanism in FLT3-ITD acute myeloid leukemia – a mechanistic and therapeutic study (opens in a new tab) Download PDF for Targeting DNA damage and repair mechanism in FLT3-ITD acute myeloid leukemia – a mechanistic and therapeutic study (opens in a new tab)

  17. Using self-associating supramolecular amphiphiles as a novel enhancer of anticancer drug delivery to treat non-muscle invasive bladder cancer

    … efficacy of the anticancer drugs mitomycin C and olaparib. Using the UM-UC-3 cell line as an in vitro model for NMIBC, SSAs and anticancer drugs were delivered in two primary methodologies: as a co-formulated treatment, and sequential treatment. Consistent synergy was observed when cells were …

    kent Download PDF for Using self-associating supramolecular amphiphiles as a novel enhancer of anticancer drug delivery to treat non-muscle invasive bladder cancer (opens in a new tab)

Page 1 of 7